Dr. Donald Thea

Professor of International Health, Boston University School of Medicine - CC


          What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Member of the Healthcare Council

Request a consultation with Donald Thea

Council Member Biography

Donald Thea, MD, is a Professor of International Health at Boston University School of Public Health, Massachusetts. He has also been the Director of the Clinical Research Unit. This unit oversees a portfolio of international clinical research in the areas of infectious diseases, tropical medicine, pneumonia, mental health, HIV diagnosis and treatment, and pharmaceutical policy. Prior to that Dr. Thea was the Scientific Director of the Health, Education and Social Development Unit at the Harvard Institute for International Development and the Founder and Director of the Travel Medicine Center at St. Luke’s-Roosevelt Hospital, New York. Dr. Thea has spent over 20 years doing clinical research on infectious and tropical diseases (including malaria), and most substantially in HIV infection. Dr. Thea was the Director of the Clinical Unit at Projet SIDA, Congo, the first, and one of the most productive international HIV research collaborations. (This is me - Update Profile)


Employment History

2000 - Unspecified
Professor of International Health, Boston University School of Medicine - CC
1998 - 2000
Associate, Harvard University
1993 - 1998
Travel Medicine Clinic Director, St. Lukes-Roosevelt Hospital
1992 - 1998
Project Director, Medical & Health Research Association of NY

GLG NewsSM Analyses by Donald Thea

Opinions and analyses expressed in G+ Insights are solely those of the author. See the Terms of Use for details.


GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

PCR detetction of Salmonella food contamination not yet ready for prime time.

May 22, 2007

New Test May Allow For Rapid Detection Of Salmonella In Meat | www.medicalnewstoday.com

PCR is an invaluable tool in the research setting but has only limited usefulness in a clinical context and, in my opinion, even more limited application for broad-based surveillance applications such as this. While PCR done well under laboratory conditions with samples spiked with known quantities of salmonella are able to be done with exquisite sensitivity (picking up all instances of salmonella) and specificity (not falsely picking salmonella when it isn't there), but getting these levels of test performance in an abbatoir or meat-packing facility will be challanging. PCR is notoriously susceptible to cross contamination and is very demanding of proper laboratory technique. Its ability to detect minutely small quantities (e.g. one bacteria or virus) of a pathogen make it prone to false positives. There are also many species of non-pathgenic Salmonella that might be detected (depending on the configuration of the primers used in the PCR) which may also result in false positives. 

Limited human-H5N1 to-human transmission documented

August 2, 2006

Bird Flu Passed From Son to Father, W.H.O. Says | www.nytimes.com

This is the best and most well-documented case of human-to-human (H2H) transmission that has yet occurred.

Genetic testing (we are told but data not yet released) indicates that a 'minor' mutation has occurred but it isn't considered to be one that confers more efficient H2H transmission.

H2H transmission as was documented between the father and son here, has likely occurred before but the issue of concern is the high infection rate within one family cluster (see previous post).

The dreaded start of Human to Human Pandemic Flu transmission? - Well not probably

August 2, 2006

Bird Flu Passed From Son to Father, W.H.O. Says | www.nytimes.com

In a closed meeting in Indonesia on Friday June 23 WHO and other experts have pronounced that the epidemiologic investigation of a family cluster of 7 cases (6 fatal) that occured at the end of May in Indonesia probably resulted in one true 3-way transmission event (person A to person B to person C).

If so, this will be the best documented individual event thus recorded. From an AP report the evidence supporting this finding is that a 'very small' mutation has occured, which was found in the last two infected individuals in the transmission chain (father and son). It is also reported that the mutations were enough to identify the concordance of the viral strains infecting these two individuals but not extensive enough to promote facilitated person-to-person spread of the virus.

Fortunate, if true because this specific strain was highly lethal (6 of 7 deaths) in this particular family. In the absence of any plausible explanation for this high lethality in this cluster, it has been suggested that this particular family has a naturally occuring genetic susceptibility to H5N1 avian influenza. No evidence has been provided to support this theory, however.

H5N1 Human Influenza: more and more like 1918 Spanish influenza

June 15, 2006

Differential Expression of Chemokines and Their Receptors in Adult and Neonatal Macrophages Infected with Human or Avian Influenza Viruses. | www.journals.uchicago.edu

This paper presents in vitro data which shows that monocyte-derived macrophages - the cells which largely flood the lungs during disease - elaborate much higher levels of chemokines to infection with H5N1 than to human influenza strains. These high levels are consistent with the 'cytokine storm' picture of rapidly progressive immune dysfunction characterized by human infection with H5N1.

Moreover, adult macrophages appear to be able to produce far higher levels of the chemokines: CCL2, CCL3, CCL5 and CXCL10. This is strong invitro support for the age-specific severity referred to above and that profound immune dysregulation is the major clinical event in severe H5N1 infection.

Good progress with H5N1 pandemic influenza DNA vaccine

June 8, 2006

Vical Avian Flu Vaccine Data Meets NIH Grant Funding Requirement | ir.vical.com

This news release reports that Vical has received accelerated access to $2.6 million in seed funding to develop a human DNA vaccine against H5N1 avian influenza after reviewing the preliminary, preclinical data recently reported (see: http://ir.vical.com/ireye/ir_site.zhtml?ticker=vicl&script=415&layout=-6&item_id=850402). The prior news release reported that, with the use of a Vical proprietary adjuvant (Vaxfectin™), there was both good immune response to a three component DNA vaccine and, more importantly, 100% protection in mice and ferrets against a lethal viral challenge with a wild type H5N1 strain.

View All GLG News SM Analyses by Donald Thea

GLG Study Groups with Donald Thea(?)

Study Group Name No. Members
Infectious Diseases Physicians (US) 866
HIV Specialists (US) 353

GLG Live Meetings with Donald Thea(?)

Donald Thea has not participated in any GLG Live Meetings.

View all GLG Live Meetings in Healthcare